Xenon Pharmaceuticals Inc has a consensus price target of $48.81, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, Wedbush, and Needham on March 1, 2024. With an average price target of $56 between RBC Capital, Wedbush, and Needham, there's an implied 30.08% upside for Xenon Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 27.76% | RBC Capital | Brian Abrahams | $56 → $55 | Maintains | Outperform | Get Alert |
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 18.47% | Wedbush | Laura Chico | $46 → $51 | Maintains | Outperform | Get Alert |
03/01/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 44.02% | Needham | Serge Belanger | $50 → $62 | Maintains | Buy | Get Alert |
01/04/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 44.02% | Citigroup | David Hoang | → $62 | Initiates | → Buy | Get Alert |
01/02/2024 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 30.08% | B of A Securities | Jason Gerberry | $52 → $56 | Maintains | Buy | Get Alert |
12/18/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 44.02% | Stifel | Stephen Willey | $53 → $62 | Maintains | Buy | Get Alert |
12/08/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 46.34% | Baird | Brian Skorney | → $63 | Initiates | → Outperform | Get Alert |
11/28/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 30.08% | RBC Capital | Brian Abrahams | $51 → $56 | Maintains | Outperform | Get Alert |
11/09/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 6.85% | Wedbush | Laura Chico | $47 → $46 | Maintains | Outperform | Get Alert |
10/24/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | — | Cantor Fitzgerald | Josh Schimmer | — | Assumes | → Overweight | Get Alert |
09/22/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 18.47% | RBC Capital | Brian Abrahams | → $51 | Reiterates | Outperform → Outperform | Get Alert |
08/22/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 34.73% | Cantor Fitzgerald | Charles Duncan | → $58 | Reiterates | Overweight → Overweight | Get Alert |
08/10/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 9.18% | Wedbush | Laura Chico | → $47 | Reiterates | Outperform → Outperform | Get Alert |
08/10/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 16.14% | Needham | Serge Belanger | → $50 | Reiterates | Buy → Buy | Get Alert |
07/17/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 18.47% | RBC Capital | Brian Abrahams | → $51 | Reiterates | Outperform → Outperform | Get Alert |
06/21/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 34.73% | Cantor Fitzgerald | Charles Duncan | → $58 | Reiterates | Overweight → Overweight | Get Alert |
06/15/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 13.82% | Guggenheim | Yatin Suneja | → $49 | Reiterates | Buy → Buy | Get Alert |
05/10/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 9.18% | Wedbush | Laura Chico | $44 → $47 | Maintains | Outperform | Get Alert |
04/25/2023 | XENE | Buy Now | Xenon Pharmaceuticals | $43.05 | 34.73% | Cantor Fitzgerald | Charles Duncan | → $58 | Initiates | → Overweight | Get Alert |
The latest price target for Xenon Pharmaceuticals (NASDAQ: XENE) was reported by RBC Capital on March 1, 2024. The analyst firm set a price target for $55.00 expecting XENE to rise to within 12 months (a possible 27.76% upside). 21 analyst firms have reported ratings in the last year.
The latest analyst rating for Xenon Pharmaceuticals (NASDAQ: XENE) was provided by RBC Capital, and Xenon Pharmaceuticals maintained their outperform rating.
There is no last upgrade for Xenon Pharmaceuticals.
There is no last downgrade for Xenon Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xenon Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xenon Pharmaceuticals was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
While ratings are subjective and will change, the latest Xenon Pharmaceuticals (XENE) rating was a maintained with a price target of $56.00 to $55.00. The current price Xenon Pharmaceuticals (XENE) is trading at is $43.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.